The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1/1b, first-in-human, multi-part study of DF6215, an engineered IL-2Rα-active agonist, to investigate the safety, tolerability, pharmacokinetics, and biological and clinical activity in patients with advanced solid tumors.
 
Benedito A. Carneiro
Consulting or Advisory Role - Seagen
Research Funding - Abbvie (Inst); Actuate Therapeutics (Inst); Agenus (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Dragonfly Therapeutics (Inst); MiNK Therapeutics (Inst); Pfizer (Inst); Pyxis (Inst); Regeneron (Inst); Repare Therapeutics (Inst)
 
Meredith McKean
Consulting or Advisory Role - Castle Biosciences (Inst); IQVIA (Inst); Merck (Inst); Moderna Therapeutics (Inst); Pfizer (Inst)
Research Funding - AADi (Inst); Alpine Immune Sciences (Inst); Arcus Biosciences (Inst); Arvinas (Inst); Ascentage Pharma Group (Inst); ASCO (Inst); Astellas Pharma (Inst); Aulos Bioscience (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); BioMed Valley Discoveries (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); C4 Therapeutics (Inst); Dragonfly Therapeutics (Inst); EMD Serono (Inst); Epizyme (Inst); Erasca, Inc (Inst); Exelixis (Inst); Foghorn Therapeutics (Inst); G1 Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); IDEAYA Biosciences (Inst); Ikena Oncology (Inst); Immvira (Inst); Infinity Pharmaceuticals (Inst); Jacobio (Inst); Kechow Pharma (Inst); Kezar Life Sciences (Inst); Kinnate Biopharma (Inst); MedImmune (Inst); Mereo BioPharma (Inst); Metabomed (Inst); Moderna Therapeutics (Inst); NBE Therapeutics (Inst); Nektar (Inst); Novartis (Inst); NucMito Pharmaceuticals (Inst); OncoC4 (Inst); Oncorus (Inst); OnKure (Inst); PACT Pharma (Inst); Pfizer (Inst); Plexxikon (Inst); Poseida (Inst); Prelude Therapeutics (Inst); Pyramid Biosciences (Inst); Regeneron (Inst); Sapience Therapeutics (Inst); Scholar Rock (Inst); Seagen (Inst); Synthorx (Inst); Tempest Therapeutics (Inst); TeneoBio (Inst); Tizona Therapeutics, Inc. (Inst); Tmunity Therapeutics, Inc. (Inst); Top Alliance BioScience (Inst); Xilio Therapeutics (Inst)
 
Cecile Vicier
Honoraria - seagen
Consulting or Advisory Role - BMSi; Daiichi Sankyo/Astra Zeneca; Novartis (Inst); Owkin; Pfizer
Research Funding - BMS Norway (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Novartis; Pfizer
 
Jennifer Brooke Valerin
Consulting or Advisory Role - AstraZeneca; Myriad Genetics
Speakers' Bureau - AstraZeneca
 
Ahmad A. Tarhini
Consulting or Advisory Role - AstraZeneca; Bayer; BioNTech; Bristol-Myers Squibb; Clinigen Group; ConcertAI; Eisai; Genentech/Roche; Instil Bio; Merck; Nested; Novartis; Partner Therapeutics; Sanofi/Regeneron
Research Funding - Acrotech Biopharma (Inst); Agenus (Inst); Agenus (Inst); Bristol-Myers Squibb (Inst); Clinigen Group (Inst); Genentech/Roche (Inst); InflaRx (Inst); Merck (Inst); OncoSec (Inst); Pfizer (Inst); Sanofi/Regeneron (Inst); Scholar Rock (Inst)
 
Vinod Ganju
Honoraria - AstraZeneca; Roche/Genentech
 
Mary M. Ruisi
Employment - C4 Therapeutics; Dragonfly Therapeutics
Stock and Other Ownership Interests - Bristol-Myers Squibb
Consulting or Advisory Role - Acumen Medical Communications
Research Funding - C4 Therapeutics (Inst); Dragonfly Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Dragonfly Therapeutics Patent for DF1001 in combination with ADC (Inst)
 
Patrick Kirby
Employment - DragonflyTherapeutics
Stock and Other Ownership Interests - DragonflyTherapeutics
Patents, Royalties, Other Intellectual Property - DragonflyTherapeutics
 
Emanuela Romano
Honoraria - Roche/Genentech
Consulting or Advisory Role - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Replimune (Inst); Roche/Genentech (Inst)
Research Funding - Amgen; Bristol-Myers Squibb; Replimune (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bristol-Myers Squibb; Roche